Amgen (NASDAQ:AMGN) Announces Earnings Results

Amgen (NASDAQ:AMGN) released its earnings results on Tuesday. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63, Zacks reports. Amgen had a return on equity of 174.71% and a net margin of 18.96%. Amgen updated its FY 2025 guidance to 20.600-21.400 EPS.

Amgen Stock Up 0.1%

Amgen stock traded up $0.40 during midday trading on Tuesday, reaching $296.70. The company’s stock had a trading volume of 3,369,327 shares, compared to its average volume of 2,722,231. The stock’s 50-day simple moving average is $287.91 and its 200-day simple moving average is $287.63. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. Amgen has a 52-week low of $253.30 and a 52-week high of $335.88. The stock has a market capitalization of $159.73 billion, a P/E ratio of 24.26, a PEG ratio of 2.61 and a beta of 0.49.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be paid a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. Amgen’s dividend payout ratio (DPR) is 77.84%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AMGN shares. Raymond James Financial started coverage on Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Citigroup increased their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Piper Sandler upped their price objective on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. Finally, Bank of America upped their price objective on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average target price of $300.94.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

Several large investors have recently added to or reduced their stakes in AMGN. Darwin Wealth Management LLC purchased a new position in shares of Amgen during the 2nd quarter valued at about $135,000. Florida Financial Advisors LLC purchased a new position in shares of Amgen during the 2nd quarter valued at about $202,000. Oxford Asset Management LLP purchased a new position in shares of Amgen during the 2nd quarter valued at about $322,000. Sivia Capital Partners LLC raised its stake in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares during the last quarter. Finally, 44 Wealth Management LLC raised its stake in shares of Amgen by 5.0% during the 2nd quarter. 44 Wealth Management LLC now owns 1,257 shares of the medical research company’s stock valued at $351,000 after buying an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.